Boris Böll

7.3k total citations · 2 hit papers
123 papers, 3.6k citations indexed

About

Boris Böll is a scholar working on Pathology and Forensic Medicine, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Boris Böll has authored 123 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Pathology and Forensic Medicine, 48 papers in Oncology and 30 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Boris Böll's work include Lymphoma Diagnosis and Treatment (50 papers), Lung Cancer Treatments and Mutations (24 papers) and Chronic Lymphocytic Leukemia Research (19 papers). Boris Böll is often cited by papers focused on Lymphoma Diagnosis and Treatment (50 papers), Lung Cancer Treatments and Mutations (24 papers) and Chronic Lymphocytic Leukemia Research (19 papers). Boris Böll collaborates with scholars based in Germany, United States and Austria. Boris Böll's co-authors include Matthias Kochanek, Alexander Shimabukuro‐Vornhagen, Michael S. von Bergwelt‐Baildon, Philipp Gödel, Hans‐Joachim Stemmler, Marion Subklewe, Max Schlaak, Hans Schlößer, Dennis A. Eichenauer and Peter Borchmann and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Immunity.

In The Last Decade

Boris Böll

106 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cytokine release syndrome

2018 1.2k citations Alexander Shimabukuro‐Vornhagen, Hans‐Joachim Stemmler et al. profile →
COVID‐19 associated pulmonary aspergillosis

2020 401 citations Philipp Koehler, Oliver A. Cornely et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Boris Böll Germany	27	1.5k	879	751	732	662	123	3.6k
Yi‐Bin Chen United States	35	1.5k 1.0×	892 1.0×	683 0.9×	1.1k 1.5×	382 0.6×	197	4.9k
Alexander Shimabukuro‐Vornhagen Germany	30	1.7k 1.1×	222 0.3×	796 1.1×	1.4k 2.0×	355 0.5×	100	3.8k
Gieri Cathomas Switzerland	38	1.8k 1.2×	464 0.5×	1.5k 2.0×	802 1.1×	622 0.9×	157	6.0k
Matthias Kochanek Germany	28	1.4k 0.9×	169 0.2×	1.1k 1.4×	1.1k 1.6×	382 0.6×	114	4.2k
Gerlinde Egerer Germany	41	1.4k 0.9×	887 1.0×	677 0.9×	194 0.3×	704 1.1×	181	4.6k
Thomas Gastinne France	26	1.4k 0.9×	814 0.9×	374 0.5×	254 0.3×	258 0.4×	127	3.0k
Rafael F. Duarte Spain	39	1.8k 1.2×	539 0.6×	963 1.3×	1.0k 1.4×	162 0.2×	163	6.1k
Carole B. Miller United States	31	1.7k 1.1×	476 0.5×	1.1k 1.5×	354 0.5×	159 0.2×	108	5.2k
Bruno Moulin France	45	1.3k 0.9×	565 0.6×	530 0.7×	1.4k 1.9×	214 0.3×	258	7.1k
Rhonda K. Yantiss United States	41	1.5k 1.0×	939 1.1×	459 0.6×	386 0.5×	244 0.4×	170	6.3k

Countries citing papers authored by Boris Böll

Since Specialization

Citations

This map shows the geographic impact of Boris Böll's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Boris Böll with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Boris Böll more than expected).

Fields of papers citing papers by Boris Böll

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Boris Böll. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Boris Böll. The network helps show where Boris Böll may publish in the future.

Co-authorship network of co-authors of Boris Böll

This figure shows the co-authorship network connecting the top 25 collaborators of Boris Böll. A scholar is included among the top collaborators of Boris Böll based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Boris Böll. Boris Böll is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fosså, Alexander, Daniel Molin, Paul J. Bröckelmann, et al.. (2025). Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy: Results from the prospective GHSG–NLG phase II BVB trial. HemaSphere. 9(3). e70099–e70099. 1 indexed citations

Lang, Fabian, Andreas Voß, Guido Kobbe, et al.. (2025). Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy in combination with dasatinib in first line treatment of Philadelphia chromosome positive acute lymphoblastic leukemia. Leukemia & lymphoma. 66(6). 1079–1087.

Hopff, Sina M., Oezguer A. Onur, Dennis A. Eichenauer, et al.. (2025). Fatal outcome of severe serotonin syndrome and acute respiratory distress syndrome after self-poisoning with paroxetine: a case report. Journal of Medical Case Reports. 19(1). 504–504.

Bröckelmann, Paul J., Boris Böll, Daniël G. M. Molin, et al.. (2024). Brentuximab Vedotin, Cyclophosphamide, Doxorubicin and Prednisone (B-CAP) First-Line Treatment of Advanced-Stage Hodgkin Lymphoma: Final Results of the GHSG-NLG Phase II Bvb Trial. Blood. 144(Supplement 1). 3054–3054.

Pfeifer, Roman, Fabian Lang, Walter Fiedler, et al.. (2024). Update on GMALL Trial 08/2013 Shows Durable Favorable Outcome of Newly Diagnosed Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) with Imatinib, Dose-Reduced Induction Followed By Stem Cell Transplantation. Blood. 144(Supplement 1). 840–840. 2 indexed citations

Böll, Boris, et al.. (2023). Communication strategies for effective family-clinician conversations in the intensive care unit: A mixed methods study. Intensive and Critical Care Nursing. 79. 103497–103497. 6 indexed citations

Teschner, Daniel, Jens Panse, Jan‐Hendrik Naendrup, et al.. (2023). Chlorhexidine gluconate‐coated gel pad dressings for prevention of central venous catheter‐related bloodstream infections in patients with hematologic diseases or autologous stem cell transplantation: A registry‐based matched‐pair analysis. European Journal Of Haematology. 111(6). 914–921. 1 indexed citations

Hentrich, Marcus, Boris Böll, Daniel Teschner, et al.. (2023). Impact of the insertion site of central venous catheters on central venous catheter-related bloodstream infections in patients with cancer: results from a large prospective registry. Infection. 51(4). 1153–1159. 2 indexed citations

Kron, Anna, et al.. (2022). Last Resort Antibiotics Costs and Reimbursement Analysis of Real-Life ICU Patients with Pneumonia Caused by Multidrug-Resistant Gram-Negative Bacteria in Germany. Healthcare. 10(12). 2546–2546. 4 indexed citations

10.

Panse, Jens, Jan‐Hendrik Naendrup, Martin Schmidt‐Hieber, et al.. (2022). Scheduled removal of central venous catheters (CVC) to prevent CVC-related bloodstream infections in patients with hematological disease or autologous stem cell transplantation: a registry-based randomized simulation-study. Annals of Hematology. 101(10). 2317–2324. 4 indexed citations

11.

Borrega, Jorge Garcia, Matthias Kochanek, Clemens Warnke, et al.. (2021). Der kritisch kranke Patient nach CAR-T-Zell-Therapie. Medizinische Klinik - Intensivmedizin und Notfallmedizin. 116(2). 121–128. 6 indexed citations

12.

Kochanek, Matthias, Alexander Shimabukuro‐Vornhagen, Gernot Beutel, et al.. (2019). Prävalenz von Krebspatienten auf deutschen Intensivstationen. Medizinische Klinik - Intensivmedizin und Notfallmedizin. 115(4). 312–319. 8 indexed citations

13.

Kochanek, Matthias, Enrico Schalk, Michael von Bergwelt‐Baildon, et al.. (2019). Management of sepsis in neutropenic cancer patients: 2018 guidelines from the Infectious Diseases Working Party (AGIHO) and Intensive Care Working Party (iCHOP) of the German Society of Hematology and Medical Oncology (DGHO). Annals of Hematology. 98(5). 1051–1069. 100 indexed citations

14.

Al‐Sawaf, Othman, et al.. (2018). Pelvic cellulitis caused by Raoultella planticola in a neutropenic patient. Journal of Infection and Chemotherapy. 25(4). 298–301. 1 indexed citations

15.

Koehler, Philipp, Norma Jung, Matthias Kochanek, et al.. (2018). ‘Lost in Nasal Space’: Staphylococcus aureus sepsis associated with Nasal Handkerchief Packing. Infection. 47(2). 307–311. 6 indexed citations

16.

Neitzke, Gerald, Boris Böll, H. Burchardi, et al.. (2017). Dokumentation der Therapiebegrenzung. Empfehlung der Sektion Ethik der Deutschen Interdisziplinären Vereinigung für Intensiv- und Notfallmedizin (DIVI) unter Mitarbeit der Sektion Ethik der Deutschen Gesellschaft für Internistische Intensivmedizin und Notfallmedizin (DGIIN). Medizinische Klinik - Intensivmedizin und Notfallmedizin. 19 indexed citations

17.

Eichenauer, Dennis A., Boris Böll, & Volker Diehl. (2014). Pharmacotherapy of Hodgkin lymphoma: standard approaches and future perspectives. Expert Opinion on Pharmacotherapy. 15(8). 1139–1151. 7 indexed citations

18.

Eich, Hans Theodor, Heinz Schmidberger, Boris Böll, et al.. (2013). The German evidence-based guidelines for Hodgkin’s lymphoma. Strahlentherapie und Onkologie. 189(6). 445–447. 3 indexed citations

19.

Rothe, Achim, Stephanie Sasse, Helen Goergen, et al.. (2012). Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience. Blood. 120(7). 1470–1472. 60 indexed citations

20.

Reiners, Katrin S., Axel Goßmann, Elke Pogge von Strandmann, et al.. (2009). Effects of the Anti-VEGF Monoclonal Antibody Bevacizumab in a Preclinical Model and in Patients With Refractory and Multiple Relapsed Hodgkin Lymphoma. Journal of Immunotherapy. 32(5). 508–512. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact